Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q3 2023 · 10-Q
Revenue$10.15K$10.15K−89.3% vs Q3 2022 Net Income-$867.35K-$867.35KN/M vs Q3 2022 EPS, diluted—
Operating Income-$961,868N/M Operating Cash Flowderived-$350,548N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
Margins · derivedOperating margin-9481.2%−8391.5 pt vs Q3 2022
Net margin-8549.5%−7542.5 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end